This week’s Immunology update highlights regulatory progress, dermatology research platform expansion, and continued partnership activity across autoimmune and immune-mediated diseases.
In Today’s Newsletter
Dive deeper
💊 Lynavoy approved in PBC itch [1] [US • 19 Mar 2026]
https://www.gsk.com/en-gb/media/press-releases/lynavoy-linerixibat-approved-by-the-us-fda/
Context: Lynavoy (linerixibat, GSK), an ileal bile acid transporter inhibitor, was studied in the Phase 3 GLISTEN trial in adults with primary biliary cholangitis and cholestatic pruritus.
Key point: The US FDA approved Lynavoy for cholestatic pruritus in adults with PBC, the first US medicine approved for this indication.
Implication: May influence prescriber choice and payer reviews pending full data.
🧴 ICOTYDE wins FDA approval in plaque psoriasis [2] [US • 18 Mar 2026]
https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide
Context: ICOTYDE (icotrokinra, Johnson & Johnson), an oral IL-23 receptor antagonist, was supported by four Phase 3 studies including 2,500 patients.
Key point: The US FDA approved ICOTYDE for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Subtilitas launches for dermatology and immunology research [3] [18 Mar 2026]
https://www.globenewswire.com/news-release/2026/03/18/3258424/0/en/Mindera-Health-and-Mountaineer-Biosciences-Launch-Subtilitas-a-Precision-Translational-Medicine-Platform-for-Dermatology-and-Immunology.html
Context: Subtilitas combines non-invasive skin sampling, molecular profiling, and AI/ML analysis from Mindera Health and Mountaineer Biosciences.
Key point: The companies launched a precision translational medicine platform aimed at biomarker discovery, patient stratification, and clinical research support in skin and immune disease.
Implication: Signals pipeline investment and modality expansion.
🔬 Mabtech and Sai expand EYRA access in the US [4] [US • 18 Mar 2026]
https://www.prnewswire.com/news-releases/mabtech-establishes-strategic-us-collaboration-with-sai-life-sciences-to-expand-access-to-eyra-multiplex-immunology-platform-302717485.html
Context: Sai Life Sciences’ Boston site will serve as a co-marketed US execution hub for Mabtech’s EYRA multiplex immunology platform.
Key point: The collaboration expands access to EYRA-based cytokine profiling and custom assay development for US biopharma and biotech clients.
Implication: Signals pipeline investment and modality expansion.
🧼 Sonoma expands Aquanil dermatology line [5] [US • 18 Mar 2026]
https://ir.sonomapharma.com/press-releases/detail/442/sonoma-pharmaceuticals-announces-launch-of-new-dermatology
Context: Sonoma Pharmaceuticals developed a hypochlorous acid-based Aquanil AD line exclusively for Persōn & Covey’s OTC dermatology channels in the United States.
Key point: The launch adds sensitive-skin products spanning mist, gel, and serum formats under the Aquanil brand.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🤝 CDR-Life hits first Boehringer milestone in autoimmune partnership [6] [EU • 23 Mar 2026]
https://www.biospace.com/press-releases/cdr-life-announces-first-milestone-achievement-in-boehringer-ingelheim-autoimmune-partnership
Context: The program is a trispecific M-gager antibody-based T cell engager designed to selectively deplete B cells, supported by in vitro and in vivo preclinical proof-of-concept studies.
Key point: CDR-Life said it achieved the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim, and Boehringer elected to proceed with further development.
Implication: Signals pipeline investment and modality expansion.
💼 Sanofi licenses KT501 from Kali Therapeutics [7] [23 Mar 2026]
https://www.reuters.com/business/healthcare-pharmaceuticals/kali-therapeutics-signs-deal-with-sanofi-develop-autoimmune-treatment-2026-03-23/
Context: KT501 is a tri-specific antibody from Kali Therapeutics, in an early-stage rheumatoid arthritis study, with Sanofi obtaining global rights under the deal.
Key point: Kali Therapeutics signed a licensing agreement with Sanofi for KT501 for several autoimmune diseases, including upfront, milestone, and royalty economics.
Implication: Signals pipeline investment and modality expansion.
🧪 Gilead moves to acquire Ouro Medicines [8] [US • 23 Mar 2026]
https://www.gilead.com/news/news-details/2026/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases
Context: The deal adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager for autoimmune disease, and includes advanced collaboration discussions with Galapagos.
Key point: Gilead agreed to acquire Ouro Medicines to add a T-cell engager program for autoimmune diseases to its inflammation portfolio.
Implication: Signals pipeline investment and modality expansion.
🩺 SkinCure adds GentleBeam to image-guided dermatology platform [9] [US • 23 Mar 2026]
https://www.prnewswire.com/news-releases/skincure-oncology-introduces-fda-cleared-gentlebeam-expanding-image-guided-capabilities-in-dermatology-practices-302722335.html
Context: GentleBeam is an FDA-cleared visualization tool using laser-induced imaging technology to support treatment planning and delivery in nonmelanoma skin cancer workflows.
Key point: SkinCure Oncology introduced GentleBeam to expand image-guided capabilities in dermatology practices using its GentleCure platform.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
Why it matters
- FDA decisions for Lynavoy and ICOTYDE add new branded options in liver-related pruritus and plaque psoriasis, both with clear named entities and defined patient groups [1][2].
- Autoimmune business development remained active, with Sanofi, Gilead, Boehringer Ingelheim, CDR-Life, Kali Therapeutics, Ouro Medicines and Galapagos all tied to B-cell or T-cell directed approaches [6][7][8].
- Dermatology research infrastructure is expanding beyond visual assessment, with Subtilitas and EYRA both positioned around molecular and multiplex decision support [3][4].
- Commercial dermatology launches continue across consumer skin care and clinic-based oncology workflows, spanning Aquanil AD and GentleBeam [5][9].
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
📚 View the full Immunology archive on our research hub page.
🎯 Catch up on the Top Immunology news from the past two weeks, curated by the LucidQuest team.
FAQ
What is Lynavoy (linerixibat) approved for?
Lynavoy, from GSK, is approved by the US FDA for cholestatic pruritus in adults with primary biliary cholangitis. The source describes it as the first US-approved medicine for that indication [1].
Who can receive ICOTYDE (icotrokinra)?
ICOTYDE is approved for adults and adolescents aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy for moderate-to-severe plaque psoriasis [2].
What does Subtilitas actually do?
Subtilitas, from Mindera Health and Mountaineer Biosciences, combines non-invasive skin sampling, molecular profiling, and AI/ML analysis to support dermatology and immunology research, including biomarker discovery and patient stratification [3].
What is KT501 in the Sanofi, Kali Therapeutics deal?
KT501 is a tri-specific antibody from Kali Therapeutics. Reuters says it is being tested in an early-stage rheumatoid arthritis study and that Sanofi obtained global rights under the licensing agreement [7].
What asset is Gilead acquiring from Ouro Medicines?
The centerpiece named in the release is OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases. Gilead says the acquisition is intended to advance this program within its inflammation portfolio [8].
What changed in the CDR-Life and Boehringer Ingelheim partnership?
CDR-Life reported a first preclinical milestone and said Boehringer Ingelheim chose to continue development of the candidate after in vitro and in vivo proof-of-concept studies [6].
Entities / Keywords
Lynavoy, linerixibat, GSK, primary biliary cholangitis, PBC, cholestatic pruritus, GLISTEN
ICOTYDE, icotrokinra, Johnson & Johnson, IL-23 receptor, IL-23R, plaque psoriasis, ICONIC
Mindera Health, Mountaineer Biosciences, Subtilitas, skin transcriptomics, biomarker discovery
Mabtech, Sai Life Sciences, EYRA, multiplex immunology, cytokine profiling
Sonoma Pharmaceuticals, Persōn & Covey, Aquanil AD, Microcyn, hypochlorous acid, HOCl
CDR-Life, Boehringer Ingelheim, M-gager, trispecific antibody, B-cell depletion
Kali Therapeutics, Sanofi, KT501, tri-specific antibody, rheumatoid arthritis
Gilead Sciences, Ouro Medicines, OM336, gamgertamig, BCMAxCD3, T-cell engager, Galapagos
SkinCure Oncology, GentleBeam, GentleCure, image-guided superficial radiation therapy, IGSRT, nonmelanoma skin cancer, NMSC
References
- https://www.gsk.com/en-gb/media/press-releases/lynavoy-linerixibat-approved-by-the-us-fda/
- https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide
- https://www.globenewswire.com/news-release/2026/03/18/3258424/0/en/Mindera-Health-and-Mountaineer-Biosciences-Launch-Subtilitas-a-Precision-Translational-Medicine-Platform-for-Dermatology-and-Immunology.html
- https://www.prnewswire.com/news-releases/mabtech-establishes-strategic-us-collaboration-with-sai-life-sciences-to-expand-access-to-eyra-multiplex-immunology-platform-302717485.html
- https://ir.sonomapharma.com/press-releases/detail/442/sonoma-pharmaceuticals-announces-launch-of-new-dermatology
- https://www.biospace.com/press-releases/cdr-life-announces-first-milestone-achievement-in-boehringer-ingelheim-autoimmune-partnership
- https://www.reuters.com/business/healthcare-pharmaceuticals/kali-therapeutics-signs-deal-with-sanofi-develop-autoimmune-treatment-2026-03-23/
- https://www.gilead.com/news/news-details/2026/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases
- https://www.prnewswire.com/news-releases/skincure-oncology-introduces-fda-cleared-gentlebeam-expanding-image-guided-capabilities-in-dermatology-practices-302722335.html